Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

ADHD MedGuide for parents

Executive Summary

A medication guide directed at parents providing information about attention deficit/hyperactivity disorder can now be accessed through the ParentsMedGuide.org online resource center, the American Academy of Child and Adolescent Psychiatry and the American Psychiatric Association announce Oct. 2. Organized around questions parents might have about ADHD, the guide provides information on symptoms, treatment options, types of medications, side effects, and co-occurring disorders. The initiative follows FDA's requirement that all manufacturers of ADHD drugs disseminate MedGuides to educate patients, care-givers and clinicians of the drugs' potential links to adverse cardiac and psychiatric events (1"The Pink Sheet" Feb. 26, 2007, p. 3)...

You may also be interested in...



ADHD Drug MedGuides Show FDA’s Focus On Consumer Risk Communications

FDA's requirement that manufacturers of attention deficit/hyperactivity drugs develop patient medication guides illustrates the growing importance to the agency of communicating risks to the public

US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising

US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

PS048851

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel